Biblio

Author Title [ Type

] Year

Filters: Author is Pulsoni, Alessandro [Clear All Filters]

Journal Article

Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VRuggero, Salvi F, Merli F, Anastasia A, Luminari S, et al. Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study. J Clin Oncol. 2016.

Pulsoni A, Cappelli LVincenzo, Ballotta L, Canichella M, Serrao A, Annechini G, D'Elia GMaria, Foà R. Current and future therapeutic approaches for the treatment of follicular lymphoma. Expert Rev Anticancer Ther. 2018.

Assanto GM, Riemma C, Malaspina F, Perrone S, De Luca ML, Pucciarini A, Annechini G, D'Elia GM, Martelli M, Foà R, et al. The current role of interferon in hairy cell leukaemia: clinical and molecular aspects. Br J Haematol. 2021.

Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VRuggero, Zanni M, Merli F, Anastasia A, Luminari S, et al. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2020;4(1):136-140.

Stathis A, Pirosa MCristina, Orsucci L, Feugier P, Tani M, Ghesquières H, Musuraca G, Rossi FGaia, Merli F, Guieze R, et al. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. Haematologica. 2024.

Nizzoli ME, Manni M, Ghiggi C, Pulsoni A, Musuraca G, Merli M, Califano C, Bari A, Massaia M, Conconi A, et al. Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi. Hematol Oncol. 2023.

Arcaini L, Bommier C, Alderuccio JPablo, Merli M, Fabbri N, Nizzoli MElena, Maurer MJ, Tarantino V, Ferrero S, Rattotti S, et al. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment. EClinicalMedicine. 2024;72:102592.

De Angelis F, Tosti MElena, Capria S, Russo E, D'Elia GMaria, Annechini G, Stefanizzi C, Foà R, Pulsoni A. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study. Leuk Res. 2015.